Feature

AYA cancer: Bridging the divide


 

What’s next?

Among the recommendations of the authors of the AYA series in Blood is a call for assessing AYA-specific therapy in future clinical trials, as well as improved collaboration between adult and pediatric teams with involvement of multidisciplinary teams.

Many centers are already working on models for collaborative care, Dr. Salsman said, citing the Fort Worth AYA Oncology Coalition led by medical director Karen Albritton, MD, as an example of a program that has been successful in “getting stakeholders on the same page, helping them have a shared vision, and working to maximize improvements in outcomes.”

Patients are also taking the lead in demanding better care and attention to their psychosocial needs, Dr. Hanna said. In the case of the community-powered advocacy organization Critical Mass, they succeeded in getting lawmakers to introduce a bill in the U.S. House of Representatives that would allow college students to defer loan payments while undergoing cancer treatment.

Pages

Recommended Reading

A wonderful life
B-Cell Lymphoma ICYMI
Melanoma twice as likely after CLL/SLL than other types of NHL
B-Cell Lymphoma ICYMI
VP Biden to AACR: Help me help you
B-Cell Lymphoma ICYMI
Unavoidable, random DNA replication errors are the most common cancer drivers
B-Cell Lymphoma ICYMI
Demystifying the diagnosis and classification of lymphoma: a guide to the hematopathologist’s galaxy
B-Cell Lymphoma ICYMI
An unusual case of primary cardiac prosthetic valve-associated lymphoma
B-Cell Lymphoma ICYMI
Ibrutinib linked to invasive fungal infections
B-Cell Lymphoma ICYMI
Durable response to pralatrexate for aggressive PTCL subtypes
B-Cell Lymphoma ICYMI
Caution urged over real-world bleeding risk with ibrutinib
B-Cell Lymphoma ICYMI
ASCO updates guidance on prophylaxis for adults with cancer-related immunosuppression
B-Cell Lymphoma ICYMI